IL-23 blockade with guselkumab potentially modifies psoriasis pathogenesis: rationale and study protocol of a phase 3b, randomised, double-blind, multicentre study in participants with moderate-to-severe plaque-type psoriasis (GUIDE)

MLA

Eyerich, Kilian, et al. IL-23 Blockade with Guselkumab Potentially Modifies Psoriasis Pathogenesis: Rationale and Study Protocol of a Phase 3b, Randomised, Double-Blind, Multicentre Study in Participants with Moderate-to-Severe Plaque-Type Psoriasis (GUIDE). 2021. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsoai&AN=edsoai.on1362826519&authtype=sso&custid=ns315887.

APA

Eyerich, K., Weisenseel, P., Pinter, A., Schäkel, K., Asadullah, K., Wegner, S., Muñoz-Elias, E. J., Bartz, H., Taut, F. J. H., & Reich, K. (2021). IL-23 blockade with guselkumab potentially modifies psoriasis pathogenesis: rationale and study protocol of a phase 3b, randomised, double-blind, multicentre study in participants with moderate-to-severe plaque-type psoriasis (GUIDE).

Chicago

Eyerich, Kilian, Peter Weisenseel, Andreas Pinter, Knut Schäkel, Khusru Asadullah, Sven Wegner, Ernesto J. Muñoz-Elias, Holger Bartz, Friedmann J. H. Taut, and Kristian Reich. 2021. “IL-23 Blockade with Guselkumab Potentially Modifies Psoriasis Pathogenesis: Rationale and Study Protocol of a Phase 3b, Randomised, Double-Blind, Multicentre Study in Participants with Moderate-to-Severe Plaque-Type Psoriasis (GUIDE).” http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsoai&AN=edsoai.on1362826519&authtype=sso&custid=ns315887.